Bavarian Nordic, an industrial biotechnology company, has completed a clinical safety report from a large Phase II study with Imvamune in HIV infected subjects that confirms the excellent safety profile of Imvamune.

Bavarian Nordic, an industrial biotechnology company, has evaluated the mature Phase II data from the therapeutic prostate cancer vaccine candidate Prostvac that had been obtained as part of the recently entered partnership with the National Cancer Institute in the US.

Bavarian Nordic's US subsidiary, BN ImmunoTherapeutics, has entered into a scientific partnership with the National Cancer Institute in the US. Under the co-operative R&D agreement, both the entities will jointly develop new immunotherapies for the treatment of prostate cancer.

Bavarian Nordic's subsidiary, BN ImmunoTherapeutics has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.

Bavarian Nordic has initiated Phase I/II clinical study with its HIV vaccine candidate MVA-BN HIV multiantigen. A Phase I/II safety and immunogenicity study in 15 HIV-infected patients (CD4 counts > 350 ul/ml) has begun enrolment in the US.